Abstract
The design, synthesis, and preliminary biological evaluation of the first potent radioligand antagonist for the P2X(7) receptor, named [(3)H]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl)-piperazine (compound 13), are reported. This compound bound to human P2X(7) receptors expressed in HEK transfected cells with K(D) and B(max) value of 3.46+/-0.1 nM and 727+/-73 fmol/mg of protein, respectively. The high affinity and facile labeling makes it a promising radioligand for a further characterization of P2X(7) receptor subtype.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Arylsulfonates / chemical synthesis*
-
Arylsulfonates / pharmacology*
-
Binding Sites
-
Drug Design
-
Evaluation Studies as Topic
-
Humans
-
Isotope Labeling / methods*
-
Ligands
-
Molecular Structure
-
Purinergic P2 Receptor Antagonists*
-
Receptors, Purinergic P2X7
-
Structure-Activity Relationship
-
Tritium / chemistry*
-
Tyrosine / analogs & derivatives*
-
Tyrosine / chemical synthesis*
-
Tyrosine / pharmacology*
Substances
-
1-(N,O-bis(isoquinolinesulfonyl)-N-methyltyrosyl)-4-(4-fluorophenyl)piperazine
-
Arylsulfonates
-
Ligands
-
P2RX7 protein, human
-
Purinergic P2 Receptor Antagonists
-
Receptors, Purinergic P2X7
-
Tritium
-
Tyrosine